All In Biotech

Drug Trial Radar · NCT04381936

Randomised Evaluation of COVID-19 Therapy

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 70,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

70,000

Planned (sponsor's estimate)

Start

Mar 19, 2020

Primary completion

Sep 30, 2028

Study completion Sep 30, 2038

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UK Research and Innovation; National Institute for Health Research, United Kingdom; Wellcome Trust; Bill and Melinda Gates Foundation; Department for International Development, United Kingdom; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections; Flu Lab
First posted
May 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Casirivimab+Imdevimab, Tocilizumab, Aspirin, Baricitinib, Empagliflozin, Sotrovimab, Molnupiravir, Paxlovid or Anakinra (children only) Influenza: Baloxavir marboxil, Oseltamivir, Corticosteroids (dexamethasone) Community-acquired pneumonia: Corticosteroids (dexamethasone)

Conditions

  • Pneumonia

Interventions

  • Lopinavir-RitonavirDrug

    Lopinavir 400mg-Ritonavir 100mg by mouth (or nasogastric tube) every 12 hours for 10 days.

  • CorticosteroidDrug

    Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. Corticosteroid (in children ≤44 weeks gestational age, or \>44 weeks gestational age with PIMS-TS only) in the form of Hydrocortisone or Methylprednisolone sodium succinate (see Protocol for timing and dosage)

  • HydroxychloroquineDrug

    Hydroxychloroquine by mouth for a total of 10 days (see Protocol for timing and dosage).

  • AzithromycinDrug

    Azithromycin 500mg by mouth (or nasogastric tube) or intravenously once daily for 10 days.

  • Convalescent plasmaBiological

    Single unit of ABO compatible convalescent plasma (275mls +/- 75 mls) intravenous per day on study days 1 (as soon as possible after randomisation) and 2 (with a minimum of 12 hour interval between 1st and 2nd units).

  • TocilizumabDrug

    Tocilizumab by intravenous infusion with the dose determined by body weight (see Protocol for dosage)

  • ImmunoglobulinBiological

    Intravenous immunoglobulin (IVIg) for children \>44 weeks gestational age and \<18 years with PIMS-TS only (see Protocol for dosage)

  • Synthetic neutralising antibodiesDrug

    Patients ≥12 years only with COVID-19 pneumonia: A single dose of REGN10933 + REGN10987 8 g (4 g of each monoclonal antibody) in 250ml 0.9% saline infused intravenously over 60 minutes +/- 15 minutes as soon as possible after randomisation

  • AspirinDrug

    150 mg by mouth (or nasogastric tube) or per rectum once daily until discharge, for adults ≥18 years old.

  • ColchicineDrug

    1 mg after randomisation followed by 500mcg 12 hours later and then 500 mcg twice daily by mouth or nasogastric tube for 10 days in total, for men ≥18 years old and women ≥55 years old only

  • BaricitinibDrug

    UK \[age ≥2 years with COVID pneumonia\] and India \[age ≥18 years with COVID-19 pneumonia\]: 4 mg once daily by mouth or nasogastric tube for 10 days in total.

  • AnakinraDrug

    For children ≥1 \<18 years old only: subcutaneously or intravenously once daily for 7 days or discharge (if sooner). NB Anakinra will be excluded from the randomisation of children \<10 kg in weight.

  • Dimethyl fumarateDrug

    Early phase assessment. UK adults ≥18 years old only (excluding those on ECMO). 120 mg every 12 hours for 4 doses followed by 240 mg every 12 hours by mouth for 8 days (10 days in total).

  • High Dose CorticosteroidDrug

    Adults ≥18 years old with hypoxia only. Dexamethasone 20 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days follow by dexamethasone 10 mg (base) once daily by mouth, nasogastric tube or intravenous infusion for 5 days.

  • EmpagliflozinDrug

    Adults ≥18 years old only. 10 mg once daily by mouth for 28 days (or until discharge, if earlier).

  • SotrovimabDrug

    UK patients ≥12 years old. 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose by intravenous infusion over 1 hour as soon as possible after randomisation.

  • MolnupiravirDrug

    Patients ≥18 years old. 800 mg twice daily for 5 days by mouth.

  • PaxlovidDrug

    UK patients ≥18 years old. 300/100 mg twice daily for 5 days by mouth.

  • Baloxavir MarboxilDrug

    Patients ≥12 years old in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection. 40mg (or 80mg if weight ≥80kg) once daily by mouth or nasogastic tube to be given on day 1 and day 4.

  • OseltamivirDrug

    Any age in the UK (or ≥18 years old in other countries), with or without SARS-CoV-2 co-infection. 75mg twice daily by mouth or nasogastric tube for five days. (See Protocol for detailed dosage information)

  • Corticosteroids (dexamethasone)Drug

    Any age in the UK (or ≥18 years old in other countries), without suspected or confirmed SARS-CoV-2 infection, and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations \<92% on room air) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)

  • Corticosteroids (dexamethasone)Drug

    Patients ≥18 years old with a diagnosis of community-acquired pneumonia (with planned antibiotic use and without suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis, or Pneumocystis jirovecii infection) 6mg once daily given orally or intravenously for ten days or until discharge (whichever happens earliest)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge)Time frame: Within 28 days after randomisation
  2. Influenza co-primary outcome: All-cause mortality (with subsidiary analysis of cause of death and death at various timepoints following discharge)Time frame: Within 28 days after randomisation
  3. Influenza co-primary outcome: Time to discharge alive from hospitalTime frame: Within the first 28-days

Locations

16 sites in 16 countries. Site status is shown where the registry gives one.

  • Belgian sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Brussels, Belgium · Recruiting

  • Estonian sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Tallinn, Estonia · Recruiting

  • French sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Paris, France · Recruiting

  • Kumasi Center for Collaborative Research in Tropical Medicine KNUST

    Kumasi, Ghana · Recruiting

  • Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases

    New Delhi, India · Completed

  • Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology

    Jakarta, Indonesia · Recruiting

  • Italian sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Roma, Italy · Recruiting

  • Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences

    Kathmandu, Nepal · Recruiting

  • Dutch sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Utrecht, Netherlands · Recruiting

  • Portuguese sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Lisbon, Portugal · Recruiting

  • Romanian sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Bucharest, Romania · Recruiting

  • Wits Health Consortium

    Johannesburg, South Africa · Recruiting

  • Spanish sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Barcelona, Spain · Recruiting

  • Swedish sites are managed by the European Clinical Research Alliance on Infectious Diseases

    Stockholm, Sweden · Recruiting

  • Nuffield Department of Population Health, University of Oxford

    Oxford, United Kingdom · Recruiting

  • Oxford University Clinical Research Unit, Centre for Tropical Medicine

    Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.